Sarepta Therapeutics Inc Stock Price, News & Analysis

Sarepta Therapeutics (NASDAQ:SRPT) has opened applications for its Route 79 Scholarship Program for the 2022-2023 academic year, expanding to include scholarships for siblings of individuals with Duchenne muscular dystrophy (DMD). Up to 15 scholarships of $5,000 each will be awarded to students living with DMD, alongside 5 additional scholarships for their siblings. The program aims to support educational pursuits and will accept applications until May 13, 2022. Since its inception, it has awarded over 70 scholarships, reflecting an ongoing commitment to the Duchenne community.

Sarepta Therapeutics (NASDAQ:SRPT) will participate in three upcoming virtual investor conferences in March 2022. These include:

• Cowen 42nd Annual Health Care Conference on March 9, 2022, at 2:10 p.m. E.T.
• Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 3:20 p.m. E.T.
• Guggenheim 3rd Annual Genomic Medicines and Rare Disease Day on March 31, 2022, at 12 p.m. E.T.

The presentations will be available via live webcast on Sarepta's website and archived for 90 days. The company focuses on precision genetic medicine for rare diseases.

Sarepta Therapeutics reported a strong performance for Q4 and full-year 2021, with total revenues of $201.5 million and $701.9 million, respectively. Net product revenues rose 46% year-over-year in Q4, reaching $178.7 million, while full-year net product revenues increased by 34% to $612.4 million. The company launched its third RNA-based therapy, AMONDYS 45, and initiated pivotal trials for SRP-5051 and SRP-9001. With over $2.1 billion in cash, Sarepta expects total revenues exceeding $880 million in 2022, demonstrating a promising outlook in precision genetic medicine.

Sarepta Therapeutics (NASDAQ:SRPT) announced on February 28, 2022, that it granted equity awards to 14 newly hired individuals as part of its 2014 Employment Commencement Incentive Plan. This grant involved options for 13,625 shares and 6,950 restricted stock units (RSUs). The options have an exercise price of $76.61 per share, equating to the closing price on the Grant Date. Vesting for options occurs over four years, while RSUs vest yearly over the same period, contingent upon continued employment.

Sarepta Therapeutics (NASDAQ:SRPT) will announce its fourth quarter and full-year 2021 financial results on March 1, 2022, after market close. The company will host a conference call at 4:30 p.m. E.T. to discuss these results and provide a corporate update. Interested parties can join the call by dialing specific numbers for domestic and international callers. Sarepta is focused on precision genetic medicine for rare diseases and has over 40 programs in development aimed at treating Duchenne muscular dystrophy and limb-girdle muscular dystrophies.

Sarepta Therapeutics (NASDAQ: SRPT) has announced a collaboration with GenEdit to develop gene editing therapeutics targeting neuromuscular diseases. Utilizing GenEdit's NanoGalaxy platform, the partnership aims to create effective non-viral delivery systems for genetic medicines. Initial in vivo results show successful delivery to muscle tissue. Sarepta has exclusive rights to license up to four neuromuscular indications. The collaboration could yield up to $57 million in payments for GenEdit, alongside future royalties on product sales, marking a significant advancement in genetic medicine.

Sarepta Therapeutics (NASDAQ:SRPT) has granted equity awards to 35 new employees as an inducement to employment, approved by its Board's Compensation Committee. The awards, totaling options for 35,575 shares and 18,350 restricted stock units (RSUs), were made under the 2014 Employment Commencement Incentive Plan. The options have an exercise price of $71.57 per share, aligning with SRPT's closing price on January 31, 2022.

The options and RSUs will vest gradually over four years, contingent upon continued employment.

Sarepta Therapeutics (NASDAQ: SRPT) announced positive topline results from Part 2 of Study SRP-9001-102, a clinical trial for SRP-9001, a gene therapy for Duchenne muscular dystrophy (DMD). Participants treated with SRP-9001 scored 2.0 points higher on the North Star Ambulatory Assessment compared to matched controls (p=0.0009). The therapy demonstrated a strong safety profile with no new safety signals or serious adverse events. The study, presented at the J.P. Morgan Healthcare Conference, reinforces confidence in SRP-9001's potential as a disease-modifying treatment for DMD.

Sarepta Therapeutics (NASDAQ:SRPT) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, showcasing topline results from Part 2 of Study SRP-9001-102. This study focuses on the investigational gene therapy SRP-9001 for children aged 4 to 7 with Duchenne muscular dystrophy. The virtual presentation is scheduled for 10:30 a.m. E.T. and will include a Q&A session. The event can be accessed live on Sarepta's investor relations website, where it will also be archived for 90 days.